Gustavo Viani: High single dose SRS is promising in oligometastatic cancer
Gustavo Viani posted on LinkedIn:
“DESTROY-2 trial shows that High single dose SRS is promising with good local control and minimal toxicity in oligometastatic cancer!!
Objective:
To report final outcomes of the DESTROY-2 trial, a phase I study assessing stereotactic radiosurgery (SRS) in treating or metastatic tumors in extracranial sites
Methods:
• Study Design: Prospective dose-escalation study in with oligometastatic cancer (1–5 lesions)
• Endpoint: Define the maximum tolerated dose (MTD) of SRS-VMAT
• Objectives: Evaluate safety, efficacy, and long-term outcomes
• Treatment: Single high-dose SRS-VMAT administered to 227 lesions in 164 across, liver, and other extracranial sites
Results:
• Dose Levels Achieved: 34 Gy for, 32 Gy for liver, 24 Gy for, and 24 Gy for other sites
• Toxicity: Minimal acute toxicity (16.5% grade 1-2, one grade 3); rare late toxicity events
• Response Rate: 94.5% overall response; progression 5.5% of cases
• Survival Rates: 2-year local control at 81.7%, overall survival at 78.7%.”
Gustavo Viani, MD is an Associate Professor in the Department of Medical Imaging, Hematology, and Oncology at Hospital das Clínicas, Faculty of Medicine of Ribeirão Preto, University of São Paulo (FMRP-USP). Dr. Viani’s research focuses on radiation oncology, with expertise in brachytherapy, stereotactic radiosurgery, dose fractionation, radiation tolerance, and overall oncology practices.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023